Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

Clinical Trials

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma

EVAX

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

SAMURAI

NEOPAX

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma

SPARCC

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

KEYNOTE-426

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

PADRES

Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC

JAVELIN Renal 101

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer

A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma

CARE1

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

A-PREDICT

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Combination of Toripalimab and JS004 Therapy for ccRCC

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

PIVOT IO 011

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

AxIn

Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma

AXIPAP

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

JAVELIN Renal 100

PrE0801

PANDORA

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

SAARCC

NAXIVA

A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus

Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

FavorAx

ATLAS

SuAx